InstalabLoading...
InstalabLoading...
Most people assume the food they eat is safe. But a family of mold toxins called aflatoxins contaminates a surprising share of the global grain, nut, and dairy supply, and your body absorbs them without any obvious symptoms. Aflatoxin M1 (AFM1) is the form your liver produces after processing the most dangerous member of this family, aflatoxin B1. Measuring AFM1 in your urine tells you whether these toxins are actually reaching your body, regardless of what food labels or safety inspections say.
This is not a standard clinical test with established disease thresholds. It is an exposure biomarker, a way to measure how much of a known cancer-causing substance your body has recently processed. That distinction matters: a detectable level does not mean you are sick, but it does mean your cells have been exposed to a substance that, over years, can damage your liver and may contribute to other health problems.
The story starts with Aspergillus molds that grow on crops like corn, peanuts, tree nuts, and grains, especially in warm and humid climates. These molds produce aflatoxin B1 (AFB1), one of the most potent naturally occurring cancer-causing substances known. When you eat contaminated food, or when dairy cows eat contaminated feed, AFB1 enters the body. Your liver's detoxification enzymes (a group called cytochrome P450) convert AFB1 into several byproducts, including AFM1.
Your body then excretes AFM1 through two main routes: urine and breast milk. In dairy animals, AFM1 passes into cow's milk at a rate of roughly 0.3% to 6.3% of the AFB1 the animal consumed. AFM1 survives pasteurization and most forms of heat processing, so it persists through the dairy supply chain. This urine test captures what your own liver has processed, giving you a direct window into your personal exposure.
More common than most people realize. An umbrella review combining multiple large analyses found AFM1 in about 66% of all dairy products tested worldwide, with an average concentration of roughly 57 ng/kg. Prevalence was especially high in pasteurized milk (89%), sterilized milk (71%), and UHT milk (68%). A 20 year review of Mediterranean countries found AFM1 in 40% of milk samples, with higher contamination in southeastern Mediterranean regions.
Urinary AFM1 studies confirm that dietary exposure translates into measurable body burden. In Bangladesh, AFM1 was detected in the urine of mill workers at high frequencies. In southern Italy, 94% of volunteers in one study exceeded the tolerable daily intake for at least one mycotoxin. Studies in the UAE found a correlation between rice consumption and higher urinary AFM1. In Brazil, urinary AFM1 was described as a very sensitive biomarker for monitoring dietary aflatoxin exposure. In short, if you eat grains, nuts, or dairy, you have likely been exposed.
Aflatoxin B1 and naturally occurring aflatoxin mixtures are classified by the International Agency for Research on Cancer as Group 1 human carcinogens, meaning there is sufficient evidence that they cause cancer in people. AFM1 itself is classified separately as Group 2B, meaning it is possibly carcinogenic to humans. It is less potent than AFB1 on a dose-for-dose basis, with an estimated 2% to 10% of its parent compound's cancer-causing strength. Laboratory studies show it can still damage DNA and can be further converted into a reactive form that harms liver cells, though these findings come primarily from cell and animal experiments.
The clearest human evidence comes from two related lines of research in China. A cohort study of over 18,000 men in Shanghai measured urinary aflatoxin metabolites (including AFM1) and tracked participants for liver cancer over several years. Separately, a study of male hepatitis B carriers found that those with detectable urinary AFM1 faced about 3.3 times the risk of developing liver cancer (hepatocellular carcinoma) compared to carriers without detectable AFM1. A study in Taiwan found that this risk was further modified by genetic differences in detoxification enzymes: people missing certain protective enzyme variants (called GSTM1 and GSTT1, which help the body neutralize toxins) faced even higher risk.
For people without chronic hepatitis B, the absolute cancer risk from AFM1 alone appears to be small. Multiple population risk assessments in Italy, Serbia, Albania, Ethiopia, and Iran estimate that current dietary AFM1 exposure adds fewer than 0.01 extra liver cancer cases per 100,000 people per year in most adult populations. Children and toddlers face higher modeled risk because they consume more milk relative to their body weight.
If you carry hepatitis B or C, though, the picture changes. The combination of chronic viral liver inflammation and aflatoxin exposure has a multiplicative effect on liver cancer risk. Knowing your AFM1 exposure level becomes more meaningful in that context.
A study of 672 people in Pakistan found that higher urinary AFM1 levels were associated with markers of type 2 diabetes risk, including increased inflammation and oxidative stress (a state where harmful molecules outnumber the body's protective defenses). This suggests AFM1 exposure may contribute to metabolic dysfunction, though this is a single observational study and causality has not been established.
For pregnant and breastfeeding women, the concern is different. A meta-analysis of aflatoxin exposure during pregnancy in Africa found associations with prematurity, low birth weight, small size for gestational age, and stillbirth. AFM1 has been detected in 53% of breast milk samples in Africa and in 89% to 100% of samples in parts of Mexico, meaning infants in high-exposure regions receive aflatoxins through breast milk. Whether AFM1 specifically impairs child growth remains debated. One risk assessment in Kenya modeled that AFM1 in milk could contribute to stunting in up to 2% to 3% of young children under worst-case assumptions, but other studies have found contradictory results.
This is where the test differs from most blood work you may be used to. There are no universally agreed-upon clinical cutpoints for urinary AFM1 that separate "normal" from "abnormal." Regulators treat aflatoxins as substances where any exposure carries some risk, so the goal is to keep levels as low as possible rather than to hit a specific target number.
What does exist are risk assessment frameworks used in population studies. Researchers typically calculate an estimated daily intake (EDI) from your urinary level and compare it to two benchmarks:
These frameworks come from population studies in Serbia, Italy, Albania, Iran, Kenya, and other countries. They consistently show that toddlers and young children face the highest modeled risk (often with HI above 1 or MOE below 10,000), while most adults fall into the lower-concern range. Your lab will report a concentration in your urine, but interpreting that number requires context about your body weight, dietary patterns, and hepatitis status.
Because AFM1 reflects recent dietary exposure (typically the past few days), a single urine sample captures only a snapshot. Several factors can shift your reading without reflecting your long-term exposure:
A single AFM1 reading is useful as a first look, but it cannot tell you whether your exposure is consistently high, occasionally spiking, or dropping after dietary changes. Because urinary AFM1 reflects only recent intake (days, not months), its value increases dramatically when you measure it more than once.
If your first result is detectable, consider retesting in 2 to 3 months after making intentional changes to your grain, nut, and dairy sourcing. If the second result drops, your changes are working. If it stays the same or rises, your exposure source may not be what you assumed. For ongoing monitoring, testing once or twice a year at consistent times (same season, similar recent diet) gives you the clearest trend. Because this is a newer measurement without standardized cutpoints, building your own data over time gives you a head start as the science matures.
If your urinary AFM1 is undetectable, your recent aflatoxin exposure is very low. No further action is needed, but periodic retesting (annually or after significant dietary changes) helps confirm you are staying in the clear.
If your level is detectable, start by identifying your most likely exposure sources. Grains (especially corn and rice), peanuts, tree nuts, and dairy products from regions with warm climates and less rigorous food safety controls are the usual suspects. Switch to brands or sources with tighter quality testing if possible, then retest in 2 to 3 months.
If your level is persistently elevated, consider adding liver function tests (ALT, AST, GGT) and hepatitis B and C screening if you have not already done so. The combination of chronic viral hepatitis and ongoing aflatoxin exposure is the scenario where risk escalates most sharply. A hepatologist or a physician experienced in environmental toxicology can help you interpret persistent exposure in the context of your liver health. For anyone with known hepatitis B or C, even modest AFM1 levels warrant closer liver surveillance.
Evidence-backed interventions that affect your Aflatoxin M1 level
Aflatoxin M1 is best interpreted alongside these tests.